サマリー

欧州のエファーマシー市場調査レポート 2027年までの予測

市場の概要
欧州のePharmacy市場の成長は、慢性疾患や感染症の発生が増加し、多疾患を抱える患者数が増加していることに起因しています。しかし、同市場では違法なオンライン薬局が存在するため、市場成長の妨げになる可能性があります。また、インターネットやヘルスケアアプリの普及率の高まりは、同市場で活動するプレーヤーに有利な機会を提供します。
ePharmacyは、オンライン薬局とも呼ばれ、インターネットを介して動作し、医薬品、薬、食品サプリメント、化粧品、医療機器などのアイテムを販売しています。ePrescribing、薬局の検索、新薬のサービス、在庫確認、オンライン相談、市販薬のオンライン注文と相談、モニタリング、リマインダー、臨床情報の管理などのサービスを提供することができる。
欧州のePharmacy市場の成長を促進する主な要因は、慢性疾患や感染症の増加、多疾病患者の増加、ePharmacy新興企業への有利な投資です。しかし、違法なオンライン薬局の存在やデータセキュリティが市場成長の妨げになる可能性があります。インターネットやヘルスケアアプリの普及率の向上は、ePharmacy市場を推進する機会を創出します。
市場セグメンテーション
タイプ別では、欧州ePharmacy市場は、処方箋と店頭販売（OTC）に区分される。製品タイプに基づき、欧州ePharmacy市場は、慢性薬、急性薬、栄養、デルモ・コスメティクス、パーソナルケア、その他に区分される。その他の製品セグメントには、医療機器、医療用品、食品、パルナッツ、その他が含まれます。
操作プラットフォームに基づき、欧州のePharmacy市場はウェブサイトとアプリに区分されています。
主要プレイヤー
Zur Rose Group（スイス）、Shop Apotheke Europe（オランダ）、Apoteket AB（スウェーデン）、lloydspharmacy（イギリス）、Medpex（ドイツ）、Medikamente-per-klick.de（ドイツ）、Apotal.de（ドイツ）、Viata online pharmacy（ベルギー）。
COVID 19の影響
私たちは、COVID-19の大流行があらゆる分野の様々な業界や業種に与える影響を継続的に追跡しています。弊社の調査レポートでは、COVID-19の産業への影響による減少や上昇を把握することができます。また、関心のある市場の需要と供給のギャップを特定するのに役立ちます。さらに、このレポートは、分析、改正された政府規制、および他の多くの有用な洞察であなたを支援します。

ページTOPに戻る

目次

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 RISING OCCURRENCE OF CHRONIC AND INFECTIOUS DISEASES
4.2.2 INCREASING PATIENTS WITH MULTIMORBIDITIES
4.2.3 LUCRATIVE INVESTMENT FOR EPHARMACY STARTUPS
4.3 RESTRAINTS
4.3.1 AVAILABILITY OF ILLEGITIMATE ONLINE PHARMACIES
4.3.2 DATA SECURITY
4.4 OPPORTUNITIES
4.4.1 INCREASING ADOPTION RATE OF INTERNET AND HEALTHCARE APPS
4.5 CHALLENGES
4.5.1 REGULATORY RESTRICTIONS RELATED TO EPHARMACY
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 CUSTOMER ACQUISITION (PREPURCHASE QUERY)
5.1.2 SERVICE CUSTOMIZATION
5.1.3 CUSTOMER PURCHASE SUPPORT
5.1.4 CUSTOMER FULFILMENT & POST-PURCHASE SUPPORT
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON EPHARMACY MARKET
5.3.1 OVERVIEW
5.3.2 IMPACT ON SUPPLY OF MEDICINES
5.3.3 IMPACT ON MAJOR PLAYERS
5.3.4 IMPACT ON AVAILABILITY OF PRODUCTS/SERVICES
5.4 REGULATORY LANDSCAPE FOR E-PHARMACIES IN EUROPE
5.4.1 REGULATORY LANDSCAPE BY COUNTRY
6 EUROPE EPHARMACY MARKET, BY TYPE
6.1 OVERVIEW
6.2 PRESCRIPTION
6.3 OVER THE COUNTER (OTC)
7 EUROPE EPHARMACY MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 CHRONIC DRUGS
7.3 ACUTE DRUGS
7.4 NUTRITION
7.5 DERMO COSMETICS
7.6 PERSONAL CARE
7.7 OTHERS
8 EUROPE EPHARMACY MARKET, BY OPERATING PLATFORM
8.1 OVERVIEW
8.2 WEBSITE
8.3 APPS
9 EUROPE EPHARMACY MARKET, BY COUNTRY
9.1 OVERVIEW
9.2 GERMANY
9.3 FRANCE
9.4 UK
9.5 ITALY
9.6 SPAIN
9.7 PORTUGAL
9.8 NETHERLANDS
9.9 TURKEY
9.10 CZECH REPUBLIC
9.11 ROMANIA
9.12 LITHUANIA
9.13 NORWAY
9.14 REST OF EUROPE
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 COMPETITIVE BENCHMARKING
10.3 MAJOR GROWTH STRATEGY IN THE EUROPE EPHARMACY MARKET
10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE EUROPE EPHARMACY MARKET
10.5 KEY DEVELOPMENT ANALYSIS
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
10.6.1 PRODUCT LAUNCH/ PRODUCT APPROVAL
10.6.2 MERGER/ACQUISITION
10.6.3 PARTNERSHIP/ AGREEMENT
10.7 FINANCIAL MATRIX
10.7.1 SALES (USD MILLION), 2020
10.8 LIST OF MAJOR START-UPS
11 COMPANY PROFILES
11.1 DR. FOX PHARMACY
11.1.1 COMPANY OVERVIEW
11.1.2 FINANCIAL OVERVIEW
11.1.3 PRODUCT/SERVICE OFFERED
11.1.4 KEY DEVELOPMENTS
11.1.5 SWOT ANALYSIS
11.1.6 KEY STRATEGIES
11.2 VIATA ONLINE PHARMACY
11.2.1 COMPANY OVERVIEW
11.2.2 FINANCIAL OVERVIEW
11.2.3 PRODUCT/SERVICE OFFERED
11.2.4 KEY DEVELOPMENTS
11.2.5 SWOT ANALYSIS
11.2.6 KEY STRATEGIES
11.3 BESTWAY GROUP LIMITED (WELL PHARMACY)
11.3.1 COMPANY OVERVIEW
11.3.2 FINANCIAL OVERVIEW
11.3.3 PRODUCT/SERVICE OFFERED
11.3.4 KEY DEVELOPMENTS
11.3.5 KEY STRATEGIES
11.4 LLOYDS PHARMACY
11.4.1 COMPANY OVERVIEW
11.4.2 FINANCIAL OVERVIEW
11.4.3 PRODUCT/SERVICE OFFERED
11.4.4 KEY DEVELOPMENTS
11.4.5 KEY STRATEGIES
11.5 APOTEK AB
11.5.1 COMPANY OVERVIEW
11.5.2 FINANCIAL OVERVIEW
11.5.3 PRODUCT/SERVICE OFFERED
11.5.4 KEY DEVELOPMENTS
11.5.5 SWOT ANALYSIS
11.5.6 KEY STRATEGIES
11.6 SHOP APOTHEKE EUROPE
11.6.1 COMPANY OVERVIEW
11.6.2 FINANCIAL OVERVIEW
11.6.3 PRODUCT/SERVICE OFFERED
11.6.4 KEY DEVELOPMENTS
11.6.5 SWOT ANALYSIS
11.6.6 KEY STRATEGIES
11.7 DR.MAX PHARMACY
11.7.1 COMPANY OVERVIEW
11.7.2 FINANCIAL OVERVIEW
11.7.3 PRODUCT/SERVICE OFFERED
11.7.4 KEY DEVELOPMENTS
11.7.5 KEY STRATEGIES
11.8 ZUR ROSE GROUP (DOCMORRIS N.V.)
11.8.1 COMPANY OVERVIEW
11.8.2 FINANCIAL OVERVIEW
11.8.3 PRODUCT/SERVICE OFFERED
11.8.4 KEY DEVELOPMENTS
11.8.5 SWOT ANALYSIS
11.8.6 KEY STRATEGIES
11.9 MEDPEX
11.9.1 COMPANY OVERVIEW
11.9.2 FINANCIAL OVERVIEW
11.9.3 PRODUCT/SERVICE OFFERED
11.9.4 KEY DEVELOPMENTS
11.9.5 KEY STRATEGIES
11.10 MEDIKAMENTE-PER-KLICK.DE
11.10.1 COMPANY OVERVIEW
11.10.2 FINANCIAL OVERVIEW
11.10.3 PRODUCT/SERVICE OFFERED
11.10.4 KEY DEVELOPMENTS
11.10.5 KEY STRATEGIES
11.11 APOTAL.DE
11.11.1 COMPANY OVERVIEW
11.11.2 FINANCIAL OVERVIEW
11.11.3 PRODUCT/SERVICE OFFERED
11.11.4 KEY DEVELOPMENTS
11.11.5 KEY STRATEGIES
11.12 PEARS HEALTH CYBER, SRO (LEKARNA.CZ)
11.12.1 COMPANY OVERVIEW
11.12.2 FINANCIAL OVERVIEW
11.12.3 PRODUCT/SERVICE OFFERED
11.12.4 KEY DEVELOPMENTS
11.12.5 KEY STRATEGIES
11.13 FARMASIET
11.13.1 COMPANY OVERVIEW
11.13.2 FINANCIAL OVERVIEW
11.13.3 PRODUCT/SERVICE OFFERED
11.13.4 KEY DEVELOPMENTS
11.13.5 KEY STRATEGIES
12 EUROPE EPHARMACY MARKET, KEY QUESTIONS BY COUNTRY
12.1 ELECTRONIC PRESCRIPTIONS
12.2 OTC SALES
12.3 PARA-PHARMACY
12.4 ONLINE PAYMENTS
12.5 DELIVERY
12.6 CENTRAL PRICING STRATEGY
12.7 SKUS BY MARKET OF COMPETITORS AND WHAT IS OVERALL 80/20 DISTRIBUTION OF SKU
12.8 CLICK AND COLLECT
12.9 LOYALTY CARD ALLOWED FOR OTC AND PARA
12.10 ADVERTISING AND DISCOUNTING
12.11 PRICE ANALYSIS FOR ONLINE VS BRICK AND MORTAR PHARMACIES
13 APPENDIX
13.1 REFERENCES
13.2 RELATED REPORTS

ページTOPに戻る

図表リスト

LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
TABLE 3 REGULATORY LANDSCAPE BY COUNTRY
TABLE 4 EUROPE: EPHARMACY MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 5 EUROPE: EPHARMACY MARKET, FOR PRESCRIPTION, BY COUNTRY, 2018–2027 (USD MILLION)
TABLE 6 EUROPE: EPHARMACY MARKET, FOR OTC, BY COUNTRY, 2018–2027 (USD MILLION)
TABLE 7 EUROPE: EPHARMACY MARKET, BY PRODUCT TYPE, 2018–2027 (USD MILLION)
TABLE 8 EUROPE: EPHARMACY MARKET, FOR CHRONIC DRUGS, BY COUNTRY, 2018–2027 (USD MILLION)
TABLE 9 EUROPE: EPHARMACY MARKET, FOR ACUTE DRUGS, BY COUNTRY, 2018–2027 (USD MILLION)
TABLE 10 EUROPE: EPHARMACY MARKET, FOR NUTRITION, BY COUNTRY, 2018–2027 (USD MILLION)
TABLE 11 EUROPE: EPHARMACY MARKET, FOR DERMO COSMETICS, BY COUNTRY, 2018–2027 (USD MILLION)
TABLE 12 EUROPE: EPHARMACY MARKET, FOR PERSONAL CARE, BY COUNTRY, 2018–2027 (USD MILLION)
TABLE 13 EUROPE: EPHARMACY MARKET, FOR OTHERS, BY COUNTRY, 2018–2027 (USD MILLION)
TABLE 14 EUROPE: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2027 (USD MILLION)
TABLE 15 EUROPE: EPHARMACY MARKET, FOR WEBSITE, BY COUNTRY, 2018–2027 (USD MILLION)
TABLE 16 EUROPE: EPHARMACY MARKET, FOR APPS, BY COUNTRY, 2018–2027 (USD MILLION)
TABLE 17 EUROPE: EPHARMACY MARKET, BY COUNTRY, 2018–2027 (USD MILLION)
TABLE 18 GERMANY: EPHARMACY MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 19 GERMANY: EPHARMACY MARKET, BY PRODUCT TYPE, 2018–2027 (USD MILLION)
TABLE 20 GERMANY: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2027 (USD MILLION)
TABLE 21 FRANCE: EPHARMACY MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 22 FRANCE: EPHARMACY MARKET, BY PRODUCT TYPE, 2018–2027 (USD MILLION)
TABLE 23 FRANCE: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2027 (USD MILLION)
TABLE 24 UK: EPHARMACY MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 25 UK: EPHARMACY MARKET, BY PRODUCT TYPE, 2018–2027 (USD MILLION)
TABLE 26 UK: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2027 (USD MILLION)
TABLE 27 ITALY: EPHARMACY MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 28 ITALY: EPHARMACY MARKET, BY PRODUCT TYPE, 2018–2027 (USD MILLION)
TABLE 29 ITALY: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2027 (USD MILLION)
TABLE 30 SPAIN: EPHARMACY MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 31 SPAIN: EPHARMACY MARKET, BY PRODUCT TYPE, 2018–2027 (USD MILLION)
TABLE 32 SPAIN: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2027 (USD MILLION)
TABLE 33 PORTUGAL: EPHARMACY MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 34 PORTUGAL: EPHARMACY MARKET, BY PRODUCT TYPE, 2018–2027 (USD MILLION)
TABLE 35 PORTUGAL: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2027 (USD MILLION)
TABLE 36 NETHERLANDS: EPHARMACY MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 37 NETHERLANDS: EPHARMACY MARKET, BY PRODUCT TYPE, 2018–2027 (USD MILLION)
TABLE 38 NETHERLANDS: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2027 (USD MILLION)
TABLE 39 TURKEY: EPHARMACY MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 40 TURKEY: EPHARMACY MARKET, BY PRODUCT TYPE, 2018–2027 (USD MILLION)
TABLE 41 TURKEY: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2027 (USD MILLION)
TABLE 42 CZECH REPUBLIC: EPHARMACY MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 43 CZECH REPUBLIC: EPHARMACY MARKET, BY PRODUCT TYPE, 2018–2027 (USD MILLION)
TABLE 44 CZECH REPUBLIC: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2027 (USD MILLION)
TABLE 45 ROMANIA: EPHARMACY MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 46 ROMANIA: EPHARMACY MARKET, BY PRODUCT TYPE, 2018–2027 (USD MILLION)
TABLE 47 ROMANIA: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2027 (USD MILLION)
TABLE 48 LITHUANIA: EPHARMACY MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 49 LITHUANIA: EPHARMACY MARKET, BY PRODUCT TYPE, 2018–2027 (USD MILLION)
TABLE 50 LITHUANIA: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2027 (USD MILLION)
TABLE 51 NORWAY: EPHARMACY MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 52 NORWAY: EPHARMACY MARKET, BY PRODUCT TYPE, 2018–2027 (USD MILLION)
TABLE 53 NORWAY: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2027 (USD MILLION)
TABLE 54 REST OF EUROPE: EPHARMACY MARKET, BY TYPE, 2018–2027 (USD MILLION)
TABLE 55 REST OF EUROPE: EPHARMACY MARKET, BY PRODUCT TYPE, 2018–2027 (USD MILLION)
TABLE 56 REST OF EUROPE: EPHARMACY MARKET, BY OPERATING PLATFORM, 2018–2027 (USD MILLION)
TABLE 57 MAJOR PLAYERS IN THE EUROPE EPHARMACY MARKET
TABLE 58 MOST ACTIVE PLAYER IN THE EUROPE EPHARMACY MARKET
TABLE 59 PRODUCT LAUNCH/ PRODUCT APPROVAL
TABLE 60 MERGER/ACQUISITION
TABLE 61 PARTNERSHIP/ AGREEMENT
TABLE 62 LIST OF MAJOR START-UPS
TABLE 63 DR. FOX PHARMACY: PRODUCT/SERVICE OFFERED
TABLE 64 VIATA ONLINE PHARMACY: PRODUCT/SERVICE OFFERED
TABLE 65 BESTWAY GROUP LIMITED (WELL PHARMACY): PRODUCT/SERVICE OFFERED
TABLE 66 BESTWAY GROUP LIMITED (WELL PHARMACY).: KEY DEVELOPMENTS
TABLE 67 LLOYDS PHARMACY: PRODUCT/SERVICE OFFERED
TABLE 68 LLOYDS PHARMACY: KEY DEVELOPMENTS
TABLE 69 APOTEKET AB: PRODUCT/SERVICE OFFERED
TABLE 70 SHOP APOTHEKE EUROPE: PRODUCT/SERVICE OFFERED
TABLE 71 SHOP APOTHEKE EUROPE: KEY DEVELOPMENTS
TABLE 72 DR. MAX PHARMACY: PRODUCT/SERVICE OFFERED
TABLE 73 DR. MAX PHARMACY: KEY DEVELOPMENTS
TABLE 74 ZUR ROSE GROUP: PRODUCT/SERVICE OFFERED
TABLE 75 ZUR ROSE GROUP: KEY DEVELOPMENTS
TABLE 76 MEDPEX: PRODUCT/SERVICE OFFERED
TABLE 77 MEDIKAMENTE-PER-KLICK.DE: PRODUCT/SERVICE OFFERED
TABLE 78 APOTAL.DE: PRODUCT/SERVICE OFFERED
TABLE 79 PEARS HEALTH CYBER, SRO (LEKARNA.CZ): PRODUCT/SERVICE OFFERED
TABLE 80 FARMASIET: PRODUCT/SERVICE OFFERED
TABLE 81 FARMASIET: KEY DEVELOPMENTS
TABLE 82 ELECTRONIC PRESCRIPTIONS
TABLE 83 OTC SALES
TABLE 84 PARA-PHARMACY
TABLE 85 ONLINE PAYMENTS
TABLE 86 DELIVERY
TABLE 87 CENTRAL PRICING STRATEGY
TABLE 88 SKUS BY MARKET OF COMPETITORS AND WHAT IS OVERALL 80/20 DISTRIBUTION OF SKU
TABLE 89 CLICK AND COLLECT
TABLE 90 LOYALTY CARD ALLOWED FOR OTC AND PARA
TABLE 91 ADVERTISING AND DISCOUNTING